The European Patent Office (EPO) has published patent application EP4301785A1, titled "EPHA2 ANTIBODIES," with an applicant of Atreca, Inc. The publication date is March 11, 2026. This document details specific antibody sequences and their potential applications, primarily in the field of oncology, as indicated by the IPC classifications.

This publication is a notice of a patent application and does not impose immediate compliance obligations. However, it is relevant for pharmaceutical companies and drug manufacturers operating in the biotechnology and oncology space, as it pertains to intellectual property rights for therapeutic antibodies. Companies should monitor the prosecution of this patent application and similar filings for potential impacts on their research, development, and commercialization strategies.